Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Dynavax ( (DVAX) ) is now available.
On August 21, 2025, Dynavax announced positive topline results from Part 1 of its Phase 1/2 clinical trial for Z-1018, a novel shingles vaccine candidate. The trial showed that Z-1018 has comparable immune responses to Shingrix, with a favorable tolerability profile, marking a significant step in Dynavax’s efforts to disrupt the shingles vaccine market. Plans are underway to advance Z-1018 into Part 2 of the trial for adults aged 70 and older, aiming to further de-risk the program before Phase 3 development.
The most recent analyst rating on (DVAX) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Dynavax stock, see the DVAX Stock Forecast page.
Spark’s Take on DVAX Stock
According to Spark, TipRanks’ AI Analyst, DVAX is a Neutral.
Dynavax’s overall stock score is primarily influenced by its strong earnings call, which highlights significant revenue growth and market share gains. However, financial performance is hindered by profitability challenges, and the lack of technical analysis data and poor valuation metrics weigh down the score.
To see Spark’s full report on DVAX stock, click here.
More about Dynavax
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative vaccines.
Average Trading Volume: 1,565,573
Technical Sentiment Signal: Sell
Current Market Cap: $1.23B
See more insights into DVAX stock on TipRanks’ Stock Analysis page.